Why Is Abbott Acquiring St. Jude?
In one of the most prodigious health-care deals in recent memory, Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire St. Jude Medical (NYSE: STJ) for $25 billion. In this analysis, we analyse the key reasons as to why Abbott might be acquiring St. Jude?
1) Abbott To Have More Pricing Power
After the completion of this deal, Abbott will be positioned to have improved pricing and negotiating power in the highly competitive medical device market. This comes at a time when hospitals are trying to bring down their supply-chain expenses, as insurance companies are trying hard to prevent them from raising the healthcare services costs.
- What’s Next For Abbott Stock After A 6% Rise This Year?
- Is Abbott Stock Undervalued At $95?
- Which Is A Better Pick – Abbott Stock Or Amgen?
- Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?
- Lower Testing Demand To Weigh On Abbott’s Q2?
- Will Abbott Stock Rebound To Its 2022 Highs?
2) Synergies From Cross-Customer Relationships
In an effort to bring down expenses, hospitals are trying to maintain their relationship with only a few vendors, which gives them the privilege of getting discounts on the products purchased. However, the combined company will be able to leverage their cross customer relationships to sell medical devices, adding to revenue synergies.
3) Slow Down In Abbott’s Existing Medical Device Business
Abbott’s vascular business has been a drag on Abbott’s overall growth. The key reasons that can be attributed to the declining trend in vascular sales are pricing pressures and foreign currency fluctuations. Although St. Jude’s overall sales also haven’t been very encouraging either, the combined company can see growth from market share expansions and synergies emerging from the cross selling of products to customers.
4) Effectively compete against rivals
With this acquisition, Abbott will be able to broaden its cardiovascular products portfolio and enter into the large cardiac rhythm management market, helping it compete effectively against its rivals, Medtronic PLC(NYSE:MDT) and Boston Scientifc Corp(NYSE:BSX). According to Abbott’s press release related to the deal, the combined company will likely be a market leader in most of the areas of the large cardiac rhythm management market. The following table shows how the combined company currently fares in various areas of the cardiovascular market:
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)